MacroGenics, Inc. Reports Decline in Quarterly Revenues
MacroGenics, Inc., a biopharmaceutical company, reported a decline in Q3 revenues to $72.8 million from $110.7 million year-over-year. Net income also fell to $16.8 million from $56.3 million. Collaborative revenues dropped significantly, while contract manufacturing revenues increased. The company plans to focus on advancing its clinical product candidates and seeks strategic collaborations and new capital to support R&D efforts, ensuring operational funding for the next year.
MacroGenics Inc ( (MGNX) ) has released its Q3 earnings. Here is a breakdown of the information MacroGenics Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the development of innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary suite of antibody technology platforms.
In its latest earnings report for the quarter ended September 30, 2025, MacroGenics, Inc. reported total revenues of $72.8 million, a decrease from $110.7 million in the same quarter of the previous year. The company’s net income for the quarter was $16.8 million, compared to $56.3 million in the prior year, reflecting a significant decline in profitability.
Key financial metrics from the report indicate a substantial drop in collaborative and other agreement revenues, which fell to $53 million from $101.4 million year-over-year. Additionally, product sales were non-existent this quarter compared to $4.1 million in the previous year. However, contract manufacturing revenues saw an increase, reaching $19.8 million from $4.6 million. The company also reported a significant increase in accounts receivable and a new liability related to future royalties, impacting its financial position.
Looking forward, MacroGenics, Inc. remains focused on advancing its proprietary product candidates in clinical development, including lorigerlimab, MGC026, and MGC028. The management anticipates relying on strategic collaborations and potential new capital to support ongoing research and development efforts, aiming to maintain sufficient resources to fund operations for at least the next twelve months.
